Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Carly, and I will be your conference operator today.
Xenon Pharmaceuticals Inc. (XENE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 5,741,666 | $192,632,894 | +2% | 3.01% |
| 2. | Driehaus Capital Richard Driehaus | 4,584,859 | $153,822,019 | +2% | 1.48% |
| 3. | Braidwell LP Alex Karnal | 2,709,875 | $90,916,306 | -8% | 3.2% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,623,039 | $88,002,958 | -3% | 0.54% |
| 5. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,325,000 | $78,003,750 | -16% | 5.75% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.81 | 700 | Officer | 700 | 2022-01-21 | Filing | |
| $24.40 | 4,000 | Officer | 4,000 | 2021-12-06 | Filing | |
| $2.22 | 15,000 | Director | 44,210 | 2017-11-15 | Filing | |
| $2.95 | 8,000 | Director | 29,210 | 2017-09-22 | Filing | |
| $2.95 | 2,000 | Director | 21,210 | 2017-09-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $41.07 | 1,149 | 31,302 | 2025-01-27 | Filing | ||
| $40.46 | 15,166 | 31,302 | 2025-01-27 | Filing | ||
| $40.20 | 22,468 | 31,302 | 2025-01-24 | Filing | ||
| $40.08 | 16,217 | 31,302 | 2025-01-23 | Filing | ||
| $41.19 | 11,510 | 0 | 2024-12-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,287,499 | $278,045,591 | 0.02% | |
| 2. | 3,789,197 | $127,127,560 | 0.02% | |
| 3. | 3,325,093 | $113,909,336 | 0.06% | |
| 4. | 3,088,730 | $103,626,892 | 0.02% | |
| 5. | 2,224,715 | $74,639,188 | 0.01% |
News See All
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript
Operator: Hello and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Xenon Pharmaceuticals, Inc. Earnings Conference Call.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and thank you for standing by. At this time, I'd like to welcome everyone to Xenon Pharmaceuticals, Inc. Third Quarter 2024 Earnings Conference Call.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Xenon Pharmaceuticals, Inc.
10 Best Healthcare Stocks to Buy Under $50
According to Michael Adams, the Lead Editor of Investing at Forbes, investments in healthcare stocks provide investors with consistent and steady returns because of the defensive nature of these stocks...
Hedge Funds are Racking Up Shares of This Healthcare Stock
The healthcare industry is considered to be a fairly defensive sector due to its need.
7 Best Mid-Cap Healthcare Stocks To Buy Now
The healthcare industry is considered to be a fairly defensive sector due to its need.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.61771, expectations were $-0.69. Xenon Pharmaceuticals Inc.
Billionaire Hedge Funds
